JLK, Neurosurgery Specialist Professor Eunjeong Ko Recruited from Seoul National University Hospital

Eunjung Ko, Director at JLK.

Stroke AI specialist JLK (CEO Dongmin Kim) announced on the 17th that it has recruited Professor Eunjeong Go of Seoul National University Hospital, a neurosurgery and medical artificial intelligence (AI) expert, as an executive of the company.

Through this recruitment, JLK has strengthened the research and clinical application of stroke AI solutions, and based on Professor Eunjeong Go’s hands-on clinical experience accumulated in neurosurgery, it will be able to accelerate innovation in the stroke workflow.

Professor Eunjeong Go (Director) earned her medical degree from Seoul National University College of Medicine, followed by a master's degree in neurosurgery and a Ph.D. in translational medicine. She has served as a specialist at the Department of Neurosurgery and the Center for Inpatient Medicine at Seoul National University Hospital, accumulating extensive clinical experience and research achievements in the field of neurosurgery.

In particular, she has conducted research on the discovery and AI application of multi-modal biomarkers such as body fluids, imaging, and biosignals for the diagnosis and prognosis prediction of neurological diseases including moyamoya disease and other cerebrovascular disorders. She was recognized for her research excellence by receiving the Neuro-oncology Paper Award (Shim Boseong Academic Award) at the 2024 Autumn Meeting of the Korean Neurosurgical Society.

JLK CEO Dongmin Kim said, “The addition of Professor Eunjeong Go will be a significant turning point in realizing the stroke workflow innovation that JLK aims for,” adding, “We will do our best to actively utilize Professor Go’s accumulated experience in stroke clinical practice to enhance the precision of stroke AI solutions and advance AI technology with a clinical focus.”

Meanwhile, JLK recently succeeded in obtaining U.S. Food and Drug Administration (FDA) 510(k) clearance for seven AI-based medical solutions (MEDIHUB Prostate, JBS-LVO, JLK-CTP, JLK-PWI, JLK-ICH, JLK-ailink, SDH). Additionally, three solutions (JLK-CTP, JLK-PWI, NCCT AI solution) have also received approval from Japan’s PMDA.

JLK plans to generate substantial overseas sales this year by focusing on additional overseas regulatory submissions and insurance reimbursement acquisition activities. In the U.S., it will concentrate on contracts with key hospitals to secure initial supply chains, while in Japan, it aims to accelerate initial sales through indirect sales via distributors.